期刊文献+

血管内皮细胞生长因子-一氧化氮轴与糖尿病肾病 被引量:3

Vascular endothelial growth factor-nitric oxide axis and diabetic nephropathy
原文传递
导出
摘要 血管内皮生长因子(VEGF)-一氧化氮(NO)耦联被称为VEGF-NO轴,其对维持肾小球血管内皮细胞功能起重要作用,其解耦联可能参与糖尿病肾病的发生、发展.内皮型一氧化氮合酶(eNOS)活性降低可能是糖尿病肾脏VEGF-NO轴解耦联的关键环节.肥胖、高脂血症以及氧化应激是导致糖尿病肾脏VEGF-NO轴解耦联的重要原因.脂联素、血红素加氧酶-1明显改善糖尿病大鼠肾小球血管内皮细胞的功能、降低白蛋白尿,其机制可能是通过抗氧化应激作用改善VEGF-NO轴的功能. The coupling of vascular endothelial growth factor (VEGF) with nitric oxide (NO),known as the VEGF-NO axis,plays a critical role in maintaining normal glomerular endothelial cell function,its uncoupling involves in the occurrence and development of diabetic nephropathy.Reduction of endothelial nitric oxide synthase (eNOS) activity is likely to be the key mechanism of VEGF-NO axial decoupling in diabetic kidney.Obesity,hyperlipidemia,and oxidative stress may be main reasons of VEGF-NO axis uncoupling in diabetes kidney.Adiponectin,heme oxygenase-1 could obviously improve glomerular endothelial cell function of diabetic rat,reduce proteinuria via resisting oxidative stress to improve the function of the VEGF-NO axis.
出处 《国际内分泌代谢杂志》 2015年第5期354-356,共3页 International Journal of Endocrinology and Metabolism
关键词 糖尿病肾病 血管内皮细胞生长因子 一氧化氮 一氧化氮合酶 氧化应激 Diabetic nephropathy Vascular endothelial growth factor Nitric oxide Nitric oxide synthase Oxidative stress
  • 相关文献

参考文献27

  • 1Nolan CJ, Daram P, Prentki M. Type 2 diabetes across genera-tions :from pathophysiology to prevention and management [ J ].Lancet,2011, 378(9786) :169-181.
  • 2Guariguata L,Whiting DR, Hambleton I,et al. Global estimatesof diabetes prevalence for 2013 and projections for 2035 [ J ].Diabetes Res Clin Pract, 2014, 103(2) : 137-149.
  • 3Packham DK, Alves TP, Dwyer JP, et al. Relative incidence ofESRD versus cardiovascular mortality in proteinuric type 2 diabe-tes and nephropathy : results from the DIAMETRIC ( DiabetesMellitus Treatment for Renal Insufficiency Consortium) database[J]. Am J Kidney Dis, 2012,59⑴:75-83.
  • 4Nakagawa T. Is endothelial dysfunction more deleterious thanpodocyte injury in diabetic nephropathy? [ J ]. Kidney Int,2013,83(6) :1202-1203.
  • 5Gilbert RE. The endothelium in diabetic nephropathy [ J]. CurrAtheroscler Rep,2014,16(5) :410.
  • 6Liu X, Zang P,Han F, et al. Renal protective effects of induc-tion of haem oxygenase-1 combined with increased adiponectin onthe glomerular vascular endothelial growth factor-nitric oxide axisin obese rats[ J]. Exp Physiol, 2015,100(7) :865-876.
  • 7Nakagawa T, Sato W, Kosugi T, et al. Uncoupling of VEGF withendothelial NO as a potential mechanism for abnormal angiogenesisin the diabetic nephropathy [ J ]. J Diabetes Res, 2013 , 2013 :184539.
  • 8von Leitner EC, Klinke A, Atzler D, et al. Pathogenic cycle be-tween the endogenous nitric oxide synthase inhibitor asymmetricaldimethylarginine and the leukocyte-derived hemoprotein my-eloperoxidase [J]. Circulation,2011,124(24) : 2735-2745.
  • 9Nakagawa T, Sato W, Glushakova 0, et al. Diabetic endothelialnitric oxide synthase knockout mice develop advanced diabeticnephropathy[ J] . J Am Soc Nephrol, 2007 , 18(2) : 539-550.
  • 10Brosius FC, Coward RJ. Podocytes, signaling pathways, and vas-cular factors in diabetic kidney disease [ J ]. Adv Chronic KidneyDis, 2014,21(3) :304-310.

同被引文献22

引证文献3

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部